Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 5, 2019 and accepted by EDGAR at Aug 5, 2019, 16:39 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $404.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $850.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $296.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $606.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $105.2m | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $188.3m | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $48.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $101.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $67.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2019-01-01 to 2019-06-30 | $151.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$18.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$113.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-04-01 to 2019-06-30 | −$5.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | −$14.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$16.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$64.8m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$87.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $29.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2019-01-01 to 2019-06-30 | $0 | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2019-06-30 | $54.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $1.19bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $4.26bn | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $546.2m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2019-06-30 | $2.62bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2019-06-30 | $459.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001723128-19-000111. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.